Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow
暂无分享,去创建一个
Masahiro Okada | Takamichi Murakami | Masatoshi Hori | Hiroaki Nagano | Yoshiyuki Sawai | Hiromitsu Onishi | T. Murakami | Y. Imai | M. Okada | Tonsok Kim | M. Hori | H. Nagano | N. Hayashi | K. Wakasa | M. Takamura | Yasuharu Imai | Norio Hayashi | Tonsok Kim | H. Onishi | Manabu Takamura | Sachiyo Kogita | Kazuto Fukuda | Kenichi Wakasa | Yoshiyuki Sawai | K. Fukuda | Takumi Igura | Osakuni Morimoto | T. Igura | S. Kogita | O. Morimoto
[1] M. Taupitz,et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. , 1995, Radiology.
[2] O. Matsui,et al. Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. , 1999, AJR. American journal of roentgenology.
[3] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.
[4] J. Bruix,et al. Management of hepatocellular carcinoma , 2005, Hepatology.
[5] Masatoshi Tanaka,et al. Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.
[6] C. Loddenkemper,et al. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. , 2009, AJR. American journal of roentgenology.
[7] H. Tsukuma,et al. Declining Incidence of Hepatocellular Carcinoma in Osaka, Japan, from 1990 to 2003 , 2008, Annals of Internal Medicine.
[8] M. Sherman,et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis , 2001, Gut.
[9] J. Bruix,et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma , 2004, Hepatology.
[10] S. D’Angelo,et al. Contrast-enhanced sonography versus biopsy for the differential diagnosis of thrombosis in hepatocellular carcinoma patients. , 2009, World journal of gastroenterology.
[11] T. Murakami,et al. Potential of Gadolinium-ethoxybenzyl-diethylenetriamine Pentaacetic Acid (Gd-EOB-DTPA) for Differential Diagnosis of Nonalcoholic Steatohepatitis and Fatty Liver in Rats Using Magnetic Resonance Imaging , 2007, Investigative radiology.
[12] J. Stachura,et al. 16,16‐Dimethyl‐PGE2 Protection Against α — Napthy lisothiocy anate – Induced Experimental Cholangitis in the Rat , 1984 .
[13] T. Murakami,et al. Hypervascular hepatocellular carcinoma: Combined dynamic MDCT and SPIO‐enhanced MRI versus combined CTHA and CTAP , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.
[14] N. Moriyama,et al. Early hepatocellular carcinoma: appearance at CT during arterial portography and CT arteriography with pathologic correlation. , 1995, Radiology.
[15] L Pagliaro,et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.
[16] Maximilian F Reiser,et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT--initial observations. , 2005, Radiology.
[17] M. Mack,et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. , 1996, Radiology.
[18] T. Murakami,et al. Superparamagnetic iron oxide–enhanced magnetic resonance images of hepatocellular carcinoma: Correlation with histological grading , 2000, Hepatology.
[19] J. Hoofnagle,et al. NIH conference. Hepatocellular carcinoma. , 1988, Annals of internal medicine.
[20] Yong Hwan Jeon,et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. , 2009, AJR. American journal of roentgenology.
[21] E. Hatano,et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma , 2009, Journal of Gastroenterology.
[22] K. Abe,et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. , 2005, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.
[23] J. Willatt,et al. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. , 2008, Radiology.
[24] S. Hirohashi,et al. Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. , 1991, Human pathology.
[25] I. Wanless,et al. Terminology of nodular hepatocellular lesions , 1995 .
[26] B. Bell,et al. A comparison of hepatopathologists' and community pathologists' review of liver biopsy specimens from patients with hepatitis C. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[27] Michiie Sakamoto,et al. Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia , 2009, Hepatology.
[28] G. D’Amico,et al. Hepatocellular carcinoma , 1991, Digestive Diseases and Sciences.
[29] Young Min Han,et al. Detection of liver metastases: Gadoxetic acid-enhanced three-dimensional MR imaging versus ferucarbotran-enhanced MR imaging. , 2010, European journal of radiology.
[30] U. Motosugi,et al. Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: Is it possible to shorten the examination time? , 2009, European Radiology.